Placebo for Bepirovirsen Solution for Injection 150 mg/mL
Sponsors
Glaxosmithkline Research & Development Limited
Conditions
ChronicHepatitis B
Phase 3
Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 1)
Active, not recruitingCTIS2023-504239-41-00
Start: 2023-01-09Target: 226Updated: 2026-01-21
Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 2)
Active, not recruitingCTIS2023-504238-23-00
Start: 2023-01-17Target: 235Updated: 2026-01-21